{
    "nctId": "NCT02437539",
    "briefTitle": "Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography",
    "officialTitle": "68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Prostate Cancer, Urinary Bladder Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Biodistribution",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. diagnosed with cancer of prostate, breast or urinary bladder\n2. capable of understanding and giving full informed consent\n\nExclusion Criteria:\n\n1. pregnancy\n2. lactation\n3. contraindication for the use of intravenous CT contrast-agencies\n4. claustrophobia",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}